WEN-JEN HWU

TitleProfessor
InstitutionMD Anderson
DepartmentMelanoma Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cho WC, Wang WL, Milton DR, Ingram DR, Nagarajan P, Curry JL, Ivan D, Lazar AJ, Hwu WJ, Prieto VG, Torres-Cabala CA, Aung PP. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Arch Pathol Lab Med. 2020 Oct 14. PMID: 33053175.
      Citations:    Fields:    
    2. Torres-Cabala C, Li-Ning-Tapia E, Hwu WJ. Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. Arch Med Res. 2020 Sep 16. PMID: 32950263.
      Citations:    Fields:    
    3. Mejbel HA, Torres-Cabala CA, Milton DR, Ivan D, Feldmeyer L, Namikawa K, Nagarajan P, Tetzlaff MT, Curry JL, Ross MI, Hwu WJ, Prieto VG, Aung PP. Prognostic significance of acral lentiginous histologic type in T1 melanoma. Mod Pathol. 2020 Aug 05. PMID: 32759976.
      Citations:    Fields:    
    4. Carlino MS, Menzies AM, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Guminski AD, Kefford R, Wu H, Ibrahim N, Homet Moreno B, Long GV. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 Oct 01; 26(19):5086-5091. PMID: 32605909.
      Citations: 1     Fields:    
    5. Ramani NS, Aung PP, Gu J, Sfamenos S, Sdringola-Maranga C, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Diab A, Prieto VG, Hwu WJ, Torres-Cabala CA. TERT amplification but not activation of canonical Wnt/ß-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. Mod Pathol. 2020 10; 33(10):2067-2074. PMID: 32404956.
      Citations:    Fields:    
    6. Chen PL, Neishaboori N, Tetzlaff MT, Chen WS, Aung PP, Curry JL, Nagarajan P, Ivan D, Hwu WJ, Prieto VG, Torres-Cabala CA. BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. Am J Dermatopathol. 2020 May; 42(5):313-321. PMID: 32310893.
      Citations:    Fields:    
    7. Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839. PMID: 32296058.
      Citations:    Fields:    Translation:Humans
    8. Pradhan D, Jour G, Milton D, Vasudevaraja V, Tetzlaff MT, Nagarajan P, Curry JL, Ivan D, Long L, Ding Y, Ezhilarasan R, Sulman EP, Diab A, Hwu WJ, Prieto VG, Torres-Cabala CA, Aung PP. Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. Cancers (Basel). 2019 Dec 16; 11(12). PMID: 31888295.
      Citations:    
    9. Kwon S, Velasquez FC, Rasmussen JC, Greives MR, Turner KD, Morrow JR, Hwu WJ, Ross RF, Zhang S, Sevick-Muraca EM. Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy. Theranostics. 2019; 9(26):8332-8343. PMID: 31754400.
      Citations: 2     Fields:    Translation:Animals
    10. Schvartsman G, Ma J, Bassett RL, Haydu LE, Amaria RN, Hwu P, Wong MK, Hwu WJ, Diab A, Patel SP, Davies MA, Hamerschlak N, Tawbi HA, Glitza Oliva IC. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. 2019 Dec 01; 125(23):4193-4202. PMID: 31398264.
      Citations: 3     Fields:    Translation:Humans
    11. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2019 Apr 17; 7(1):107. PMID: 30995944.
      Citations:    Fields:    
    12. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019 04 01; 30(4):582-588. PMID: 30715153.
      Citations: 50     Fields:    Translation:HumansCTClinical Trials
    13. McQuade JL, Homsi J, Torres-Cabala CA, Bassett R, Popuri RM, James ML, Vence LM, Hwu WJ. A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. BMC Cancer. 2018 Dec 19; 18(1):1274. PMID: 30567529.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    14. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942. PMID: 30361511.
      Citations: 1     Fields:    
    15. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941. PMID: 30361510.
      Citations:    Fields:    
    16. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 Dec 01; 24(23):6098. PMID: 30510087.
      Citations: 3     Fields:    
    17. Bhatty M, Kato S, Piha-Paul SA, Naing A, Subbiah V, Huang HJ, Karp DD, Tsimberidou AM, Zinner RG, Hwu WJ, Javle M, Patel SP, Hu MI, Varadhachary GR, Conley AP, Ramzanali NM, Holley VR, Kurzrock R, Meric-Bernstam F, Kwang Chae Y, Kim KB, Falchook GS, Janku F. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472. PMID: 30383888.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    18. Vera-Aguilera J, Bedikian AY, Bassett RL, Hwu WJ, Kim KB, Qin Y, Cain S, Washington EW, Davies MA, Patel SM, Homsi J, Papadopoulos NE, Hwu P, Patel SP. Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver. Am J Clin Oncol. 2018 Nov; 41(11):1132-1136. PMID: 29509591.
      Citations:    Fields:    
    19. Sagiv O, Thakar SD, Kandl TJ, Ford J, Sniegowski MC, Hwu WJ, Esmaeli B. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma. JAMA Ophthalmol. 2018 11 01; 136(11):1236-1241. PMID: 30352118.
      Citations: 6     Fields:    Translation:Humans
    20. Kim K, Chung TH, Etzel CJ, Kim J, Ryu H, Kim DW, Hwu P, Hwu WJ, Patel SP, Liu M, Kim KB. Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. Cancer Epidemiol. 2018 12; 57:80-84. PMID: 30347335.
      Citations: 1     Fields:    Translation:Humans
    21. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab A. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018 10 11; 6(1):103. PMID: 30305177.
      Citations: 13     Fields:    Translation:Humans
    22. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654. PMID: 30297909.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    23. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428. PMID: 29848573.
      Citations: 9     Fields:    Translation:HumansCells
    24. Ghosh P, Chandler AG, Hobbs BP, Sun J, Rong J, Hong D, Subbiah V, Janku F, Naing A, Hwu WJ, Ng CS. Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364. PMID: 29189398.
      Citations:    Fields:    Translation:Humans
    25. Joseph RW, Elassaiss-Schaap J, Kefford R, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud A, Dronca R, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone A, Zhang J, Kang SP, Ebbinghaus S, Anderson KM, Gangadhar TC. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clin Cancer Res. 2018 10 15; 24(20):4960-4967. PMID: 29685882.
      Citations: 25     Fields:    
    26. Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol. 2018 Jul; 45(7):504-507. PMID: 29633300.
      Citations: 1     Fields:    Translation:Humans
    27. Thakar S, Kandl T, Sagiv O, Tripathy D, Tetzlaff MT, Kapur S, Myers J, Hwu WJ, Jaber BMY, Esmaeli B. Desmoplastic Melanoma of the Periorbital Region. Ophthalmic Plast Reconstr Surg. 2018 Mar/Apr; 34(2):e48-e52. PMID: 29194286.
      Citations:    Fields:    Translation:Humans
    28. Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018 02 22; 3(4). PMID: 29467321.
      Citations: 13     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    29. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283. PMID: 29387478.
      Citations:    
    30. Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815. PMID: 29358500.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    31. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193. PMID: 29361468.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    32. Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 01 18; 553(7688):347-350. PMID: 29320474.
      Citations: 42     Fields:    Translation:HumansCells
    33. Trinh VA, Joseph J, Hwu WJ. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update. Discov Med. 2018 01; 25(135):31-40. PMID: 29466692.
      Citations: 1     Fields:    Translation:Humans
    34. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol. 2018 06 10; 36(17):1668-1674. PMID: 29283791.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    35. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 01 05; 359(6371):97-103. PMID: 29097493.
      Citations: 426     Fields:    Translation:HumansAnimals
    36. Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS. Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. J Immunother. 2017 Nov/Dec; 40(9):334-340. PMID: 29028788.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    37. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 02; 171(4):934-949.e16. PMID: 29033130.
      Citations: 180     Fields:    Translation:HumansCells
    38. Yennurajalingam S, Kang DH, Hwu WJ, Padhye NS, Masino C, Dibaj SS, Liu DD, Williams JL, Lu Z, Bruera E. Cranial Electrotherapy Stimulation for the Management of Depression, Anxiety, Sleep Disturbance, and Pain in Patients With Advanced Cancer: A Preliminary Study. J Pain Symptom Manage. 2018 02; 55(2):198-206. PMID: 28870799.
      Citations: 1     Fields:    Translation:Humans
    39. Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 09; 18(9):1202-1210. PMID: 28729151.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    40. Ramani N, Aung PP, Hwu WJ, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Prieto VG, Torres-Cabala CA. Aberrant expression of FLI-1 in melanoma. J Cutan Pathol. 2017 Sep; 44(9):790-793. PMID: 28605142.
      Citations:    Fields:    Translation:Humans
    41. Ford J, Thuro BA, Thakar S, Hwu WJ, Richani K, Esmaeli B. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. Ophthalmic Plast Reconstr Surg. 2017 Jul/Aug; 33(4):e82-e85. PMID: 27662198.
      Citations: 3     Fields:    Translation:Humans
    42. Trinh VA, Zobniw C, Hwu WJ. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opin Drug Saf. 2017 Aug; 16(8):933-940. PMID: 28627943.
      Citations: 1     Fields:    Translation:Humans
    43. Patel SP, Kim DW, Bassett RL, Cain S, Washington E, Hwu WJ, Kim KB, Papadopoulos NE, Homsi J, Hwu P, Bedikian AY. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol Immunother. 2017 Oct; 66(10):1359-1366. PMID: 28612140.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    44. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379). PMID: 28251903.
      Citations: 93     Fields:    Translation:HumansCells
    45. Chakravarti N, Ivan D, Trinh VA, Glitza IC, Curry JL, Torres-Cabala C, Tetzlaff MT, Bassett RL, Prieto VG, Hwu WJ. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res. 2017 02; 27(1):24-31. PMID: 27768639.
      Citations: 1     Fields:    Translation:HumansCells
    46. Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 02; 5(2):100-105. PMID: 28062513.
      Citations: 14     Fields:    Translation:HumansCells
    47. Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176. PMID: 27859479.
      Citations: 22     Fields:    Translation:Humans
    48. McQuade JL, Posada LP, Lecagoonporn S, Cain S, Bassett RL, Patel SP, Hwu WJ, Hwu P, Davies MA, Bedikian AY, Amaria RN. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 2016 12; 26(6):604-608. PMID: 27540836.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    49. Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 12; 34(34):4102-4109. PMID: 27863197.
      Citations: 113     Fields:    Translation:HumansCTClinical Trials
    50. Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64. PMID: 27124486.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    51. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37. PMID: 27301722.
      Citations: 161     Fields:    Translation:HumansCells
    52. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. PMID: 27092830.
      Citations: 228     Fields:    Translation:HumansCTClinical Trials
    53. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 05 01; 34(13):1510-7. PMID: 26951310.
      Citations: 165     Fields:    Translation:HumansCTClinical Trials
    54. Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97. PMID: 26364516.
      Citations: 19     Fields:    Translation:Humans
    55. McAleer MF, Kim DW, Trinh VA, Hwu WJ. Management of melanoma brain metastases. Melanoma Manag. 2015 Aug; 2(3):225-239. PMID: 30190852.
      Citations:    
    56. Glitza IC, Haymaker C, Bernatchez C, Vence L, Rohlfs M, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, Patel SP, Woodman SE, Hwu WJ, Radvanyi LG, Davies MA, Papadopoulos NE, Hwu P. Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunol Res. 2015 Nov; 3(11):1201-6. PMID: 26216417.
      Citations: 9     Fields:    Translation:HumansCells
    57. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10. PMID: 26058727.
      Citations: 7     Fields:    Translation:Humans
    58. Metcalfe W, Anderson J, Trinh VA, Hwu WJ. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. Discov Med. 2015 May; 19(106):393-401. PMID: 26105702.
      Citations: 5     Fields:    Translation:Humans
    59. Torossian NM, Wallace RT, Hwu WJ, Bedikian AY. Metastasis of ciliary body melanoma to the contralateral eye: a case report and review of uveal melanoma literature. Case Rep Oncol Med. 2015; 2015:427163. PMID: 25874144.
      Citations:    
    60. Kim DW, Trinh VA, Hwu WJ. Ipilimumab in the treatment of advanced melanoma - a clinical update. Expert Opin Biol Ther. 2014 Nov; 14(11):1709-18. PMID: 25250971.
      Citations: 3     Fields:    Translation:HumansAnimals
    61. Trinh VA, You Y, Hwu WJ. Treatment of BRAF-mutated advanced cutaneous melanoma. Chin Clin Oncol. 2014 Sep; 3(3):28. PMID: 25841454.
      Citations: 3     Fields:    
    62. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515. PMID: 25148578.
      Citations: 39     Fields:    Translation:Humans
    63. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, Woodman SE, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma. Melanoma Res. 2014 Aug; 24(4):342-8. PMID: 24743052.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    64. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17. PMID: 25034862.
      Citations: 515     Fields:    Translation:HumansCTClinical Trials
    65. Curry JL, Tetzlaff MT, Nicholson K, Duvic M, Kim KB, Tsai KY, Hwu WJ, Hong DS, Prieto VG, Torres-Cabala CA. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61. PMID: 24950418.
      Citations: 1     Fields:    Translation:Humans
    66. Plimack ER, Desai JR, Issa JP, Jelinek J, Sharma P, Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu WJ. A phase I study of decitabine with pegylated interferon a-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs. 2014 Oct; 32(5):969-75. PMID: 24875133.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    67. Yorio JT, Mays SR, Ciurea AM, Cohen PR, Wang WL, Hwu WJ, Gonzalez N, Richard JL, Kim KB. Case of vemurafenib-induced Sweet's syndrome. J Dermatol. 2014 Sep; 41(9):817-20. PMID: 24617955.
      Citations: 10     Fields:    Translation:Humans
    68. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. PMID: 23724846.
      Citations: 1182     Fields:    Translation:HumansCTClinical Trials
    69. Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86. PMID: 23603862.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    70. Curry JL, Falchook GS, Hwu WJ, Torres-Cabala CA, Duvic M, Tetzlaff MT, Prieto VG. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8. PMID: 22878367.
      Citations: 1     Fields:    Translation:Humans
    71. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70. PMID: 23032743.
      Citations: 110     Fields:    Translation:HumansCellsCTClinical Trials
    72. Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012; 7(9):e45183. PMID: 23028833.
      Citations: 27     Fields:    Translation:HumansCells
    73. Alvarado G, Noor R, Bassett R, Papadopoulos NE, Kim KB, Hwu WJ, Bedikian A, Patel S, Hwu P, Davies MA. Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res. 2012 Aug; 22(4):310-5. PMID: 22584956.
      Citations: 13     Fields:    Translation:Humans
    74. Chen LL, Gouw L, Sabripour M, Hwu WJ, Benjamin RS. Combining targeted therapy with immunotherapy (interferon-a): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies. Oncoimmunology. 2012 Aug 01; 1(5):773-776. PMID: 22934279.
      Citations:    
    75. Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012 Sep; 39(9):821-5. PMID: 22809251.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    76. Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther. 2012 Aug; 12(8):1087-99. PMID: 22694288.
      Citations: 9     Fields:    Translation:Humans
    77. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28; 366(26):2455-65. PMID: 22658128.
      Citations: 2303     Fields:    Translation:HumansCTClinical Trials
    78. Trinh VA, Hwu WJ. Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther. 2012 Jun; 12(6):773-82. PMID: 22500861.
      Citations: 8     Fields:    Translation:HumansAnimals
    79. Bronstein Y, Ng CS, Rohren E, Ross MI, Lee JE, Cormier J, Johnson VE, Hwu WJ. PET/CT in the management of patients with stage IIIC and IV metastatic melanoma considered candidates for surgery: evaluation of the additive value after conventional imaging. AJR Am J Roentgenol. 2012 Apr; 198(4):902-8. PMID: 22451559.
      Citations: 12     Fields:    Translation:Humans
    80. Trinh VA, Hwu WJ. Chemoprevention for brain metastases. Curr Oncol Rep. 2012 Feb; 14(1):63-9. PMID: 22006097.
      Citations: 4     Fields:    Translation:Humans
    81. Noor R, Bedikian AY, Mahoney S, Bassett R, Kim K, Papadopoulos N, Hwu WJ, Hwu P, Homsi J. Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy. Support Care Cancer. 2012 Oct; 20(10):2583-8. PMID: 22274951.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    82. Davies MA, Fox PS, Papadopoulos NE, Bedikian AY, Hwu WJ, Lazar AJ, Prieto VG, Culotta KS, Madden TL, Xu Q, Huang S, Deng W, Ng CS, Gupta S, Liu W, Dancey JE, Wright JJ, Bassett RL, Hwu P, Kim KB. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8. PMID: 22223528.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    83. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu WJ, Homsi J, Davies M, McIntyre S, Hwu P. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol. 2011 Dec; 34(6):603-10. PMID: 21150567.
      Citations: 13     Fields:    Translation:Humans
    84. Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011 Dec; 197(6):W992-W1000. PMID: 22109345.
      Citations: 40     Fields:    Translation:Humans
    85. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 2011 Aug; 21(4):357-63. PMID: 21738104.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    86. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91. PMID: 21632855.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    87. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, Conry R, Thompson JA, Hwu WJ, Engelen K, Agarwala SS, Keilholz U, Eggermont AM, Spatz A. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011 Jul; 47(10):1476-83. PMID: 21600759.
      Citations: 58     Fields:    Translation:HumansCTClinical Trials
    88. Alvarado GC, Papadopoulos NE, Hwu WJ, Bedikian AY, Homsi J, Myers JN, Bronstein Y, Bassett RL, Hwu P, Kim KB. Pelvic computed tomography scans for surveillance in patients with primary melanoma in the head and neck. Melanoma Res. 2011 Apr; 21(2):127-30. PMID: 21169870.
      Citations: 2     Fields:    Translation:Humans
    89. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim KB, Hwu WJ, McIntyre S, Rohlfs M, Homsi J, Hwu P. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. 2011 Feb; 21(1):84-90. PMID: 21102360.
      Citations: 3     Fields:    Translation:Humans
    90. Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, Prieto VG, Ng CS. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol. 2011 Mar; 66(3):224-36. PMID: 21295201.
      Citations: 7     Fields:    Translation:Humans
    91. Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res. 2010 Dec; 20(6):501-6. PMID: 20859231.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    92. Homsi J, Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res. 2010 Dec; 20(6):507-10. PMID: 20881508.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    93. Bedikian AY, Silverman JA, Papadopoulos NE, Kim KB, Hagey AE, Vardeleon A, Hwu WJ, Homsi J, Davies M, Hwu P. Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J Clin Pharmacol. 2011 Aug; 51(8):1205-12. PMID: 20978276.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    94. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011 Apr 15; 117(8):1687-96. PMID: 20960525.
      Citations: 119     Fields:    Translation:Humans
    95. Neyns B, Tosoni A, Hwu WJ, Reardon DA. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15; 116(12):2868-77. PMID: 20564393.
      Citations: 28     Fields:    Translation:Humans
    96. Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon a-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Mar; 67(3):657-66. PMID: 20509027.
      Citations: 6     Fields:    Translation:Humans
    97. Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol. 2009 Oct; 32(5):509-14. PMID: 19506454.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    98. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009 Aug; 27(7):756-63. PMID: 19440934.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    99. Homsi J, Bedikian AY, Kim KB, Papadopoulos NE, Hwu WJ, Mahoney SL, Hwu P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res. 2009 Aug; 19(4):238-42. PMID: 19521262.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    100. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf. 2009 Jul; 8(4):493-9. PMID: 19435405.
      Citations: 17     Fields:    Translation:Humans
    101. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9. PMID: 19430405.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    102. Kim KB, Hwu WJ, Papadopoulos NE, Bedikian AY, Camacho LH, Ng C, Hernandez IM, Frost AM, Jack MA, Hwu P. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2009 Jun; 64(1):161-7. PMID: 19002462.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    103. Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008 Jul; 26(6):624-33. PMID: 18584354.
      Citations: 26     Fields:    Translation:Humans
    104. Bedikian AY, Johnson MM, Warneke CL, McIntyre S, Papadopoulos N, Hwu WJ, Kim K, Hwu P. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol. 2008 Apr; 5(2):201-7. PMID: 18569391.
      Citations: 7     Fields:    Translation:Humans
    105. Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH, Gutin PH. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008 Apr; 10(2):199-207. PMID: 18287337.
      Citations: 59     Fields:    Translation:Humans
    106. Mitchell MS, Abrams J, Thompson JA, Kashani-Sabet M, DeConti RC, Hwu WJ, Atkins MB, Whitman E, Ernstoff MS, Haluska FG, Jakowatz JG, Das Gupta TK, Richards JM, Samlowski WE, Costanzi JJ, Aronson FR, Deisseroth AB, Dudek AZ, Jones VE. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007 May 20; 25(15):2078-85. PMID: 17513813.
      Citations: 13     Fields:    Translation:Humans
    107. Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, Coit DG, Wong WD, Weiser MR. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006 Dec; 244(6):1012-7. PMID: 17122627.
      Citations: 42     Fields:    Translation:Humans
    108. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006 Oct 15; 107(8):1883-90. PMID: 16986123.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    109. Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Jun 01; 106(11):2445-51. PMID: 16639739.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    110. Thompson MA, Warner NB, Hwu WJ. Hypertrophic osteoarthropathy associated with metastatic melanoma. Melanoma Res. 2005 Dec; 15(6):559-61. PMID: 16314744.
      Citations: 3     Fields:    Translation:Humans
    111. Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ, Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005 Jun 15; 103(12):2590-7. PMID: 15861414.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    112. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005 Jun; 6(6):438-9. PMID: 15925823.
      Citations: 10     Fields:    Translation:Humans
    113. Chapman PB, Williams L, Salibi N, Hwu WJ, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine. 2004 Jul 29; 22(21-22):2904-9. PMID: 15246627.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    114. Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res. 2004 Jul 15; 10(14):4717-23. PMID: 15269144.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    115. Lohmann CM, Hwu WJ, Iversen K, Jungbluth AA, Busam KJ. Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Melanoma Res. 2003 Dec; 13(6):595-601. PMID: 14646623.
      Citations: 7     Fields:    Translation:HumansCells
    116. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003 Nov 01; 9(14):5214-20. PMID: 14614001.
      Citations: 28     Fields:    Translation:HumansPHPublic Health
    117. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003 Sep 01; 21(17):3351-6. PMID: 12947072.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    118. Busam KJ, Sachs DL, Coit DG, Halpern A, Hwu WJ. Eruptive melanotic macules and papules associated with adenocarcinoma. J Cutan Pathol. 2003 Aug; 30(7):463-9. PMID: 12859746.
      Citations:    Fields:    Translation:Humans
    119. Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C, Chapman PB. Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res. 2003 Apr; 13(2):189-96. PMID: 12690304.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    120. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 2003 Feb; 21(1):99-101. PMID: 12795534.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    121. Lamb LA, Halpern AC, Hwu WJ. Diagnosis and management of stage I/II melanoma. Semin Oncol Nurs. 2003 Feb; 19(1):22-31. PMID: 12638378.
      Citations:    Fields:    Translation:Humans
    122. Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res. 2002 Aug; 12(4):381-7. PMID: 12170188.
      Citations: 1     Fields:    Translation:Humans
    123. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002 Jun 01; 20(11):2610-5. PMID: 12039921.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    124. Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002 May; 8(5):967-72. PMID: 12006508.
      Citations: 19     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    125. Hwu WJ, Raizer J, Panageas KS, Lis E. Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. Lancet Oncol. 2001 Oct; 2(10):634-5. PMID: 11902555.
      Citations: 1     Fields:    Translation:Humans
    126. Pollak JS, Burdge CM, Rosenblatt M, Houston JP, Hwu WJ, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J Vasc Interv Radiol. 2001 Feb; 12(2):201-8. PMID: 11265884.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    127. Hwu WJ. New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 13):25-8. PMID: 11204670.
      Citations: 4     Fields:    Translation:Humans
    128. Klimek VM, Wolchok JD, Chapman PB, Houghton AN, Hwu WJ. Systemic chemotherapy. Clin Plast Surg. 2000 Jul; 27(3):451-61, ix-x. PMID: 10941565.
      Citations: 2     Fields:    Translation:Humans
    129. Olson JA, Jaques DP, Coit DG, Hwu WJ. Staging work-up and post-treatment surveillance of patients with melanoma. Clin Plast Surg. 2000 Jul; 27(3):377-90, viii. PMID: 10941559.
      Citations: 3     Fields:    Translation:Humans
    130. Poggi SH, Madison JF, Hwu WJ, Bayar S, Salem RR. Colonic melanoma, primary or regressed primary. J Clin Gastroenterol. 2000 Jun; 30(4):441-4. PMID: 10875478.
      Citations: 15     Fields:    Translation:Humans
    131. Stephens PL, Ariyan S, Ocampo RV, Poo WJ. The predictive value of lymphoscintigraphy for nodal metastases of cutaneous melanoma. Conn Med. 1999 Jul; 63(7):387-90. PMID: 10461406.
      Citations: 1     Fields:    Translation:Humans
    132. Hwu WJ, Salem RR, Pollak J, Rosenblatt M, D'Andrea E, Leffert JJ, Faraone S, Marsh JC, Pizzorno G. A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. Oncol Res. 1999; 11(11-12):529-37. PMID: 10905565.
      Citations: 8     Fields:    Translation:Humans
    133. Ariyan S, Poo WJ. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery. 1998 Mar; 123(3):335-43. PMID: 9526527.
      Citations:    Fields:    Translation:Humans
    134. Hwu WJ, Mozdziesz DE. Molecular basis for thymidine modulation of the efficacy and toxicity of alkylating agents. Pharmacol Ther. 1997 Oct-Dec; 76(1-3):101-16. PMID: 9535172.
      Citations:    Fields:    Translation:HumansAnimals
    135. Schultz MZ, Buzaid AC, Poo WJ. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res. 1997 Apr; 7(2):147-51. PMID: 9167181.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    136. Ariyan S, Poo WJ, Bolognia J. Regional isolated perfusion of extremities for melanoma: a 20-year experience with drugs other than L-phenylalanine mustard. Plast Reconstr Surg. 1997 Apr; 99(4):1023-9. PMID: 9091898.
      Citations: 2     Fields:    Translation:Humans
    137. Poo WJ, Guo X, Haslund B, Mozdziesz DE. Immunomodulation and enhancement of antitumor activity by co-administration of 1,3-bis(2-chloroethyl)-1-nitrosourea and thymidine. Biochem Pharmacol. 1997 Mar 07; 53(5):705-13. PMID: 9113090.
      Citations: 1     Fields:    Translation:AnimalsCells
    138. Sasson HN, Poo WJ, Bakas MH, Ariyan S. Prolonged survival in patients with advanced melanoma treated with neoadjuvant chemotherapy followed by resection. Ann Plast Surg. 1996 Sep; 37(3):286-92. PMID: 8883727.
      Citations: 3     Fields:    Translation:Humans
    139. Mani S, Poo WJ. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol. 1996 Apr; 19(2):149-53. PMID: 8610639.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    140. Mani S, Todd M, Poo WJ. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma. Am J Clin Oncol. 1996 Apr; 19(2):187-9. PMID: 8610647.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    141. Ariyan S, Poo WJ, Bolognia J, Buzaid A, Ariyan T. Multiple primary melanomas: data and significance. Plast Reconstr Surg. 1995 Nov; 96(6):1384-9. PMID: 7480238.
      Citations: 3     Fields:    Translation:Humans
    142. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol. 1995 Jul; 154(1):35-40. PMID: 7539867.
      Citations: 18     Fields:    Translation:Humans
    143. Buzaid AC, Pizzorno G, Marsh JC, Ravikumar TS, Murren JR, Todd M, Strair RK, Poo WJ, Hait WN. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study. Cancer Chemother Pharmacol. 1995; 36(5):373-8. PMID: 7634378.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    144. Buzaid AC, Sandler AB, Hayden CL, Scinto J, Poo WJ, Clark MB, Hotchkiss S. Neuron-specific enolase as a tumor marker in metastatic melanoma. Am J Clin Oncol. 1994 Oct; 17(5):430-1. PMID: 8092117.
      Citations: 1     Fields:    Translation:Humans
    145. Buzaid AC, Sandler AB, Hayden CL, Scinto J, Poo WJ, Clark MB, Hotchkiss S. Correlation between lipid-associated sialic acid and tumor burden in melanoma. Int J Biol Markers. 1994 Oct-Dec; 9(4):247-50. PMID: 7836804.
      Citations:    Fields:    Translation:Humans
    146. Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, Ariyan S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol. 1993 Apr; 11(4):638-43. PMID: 8478659.
      Citations: 10     Fields:    Translation:Humans
    147. Poo WJ, Conrad L, Janeway CA. Receptor-directed focusing of lymphokine release by helper T cells. Nature. 1988 Mar 24; 332(6162):378-80. PMID: 2965306.
      Citations: 72     Fields:    Translation:AnimalsCells
    148. Cesario TC, Slater L, Poo WJ, Spindler B, Walter B, Gorse G, Carandang G. The effect of hydrocortisone on the production of gamma-interferon and other lymphokines by human peripheral blood mononuclear cells. J Interferon Res. 1986 Aug; 6(4):337-47. PMID: 3021873.
      Citations: 5     Fields:    Translation:HumansCells
    149. Poo MM, Poo WJ, Lam JW. Lateral electrophoresis and diffusion of Concanavalin A receptors in the membrane of embryonic muscle cell. J Cell Biol. 1978 Feb; 76(2):483-501. PMID: 10605452.
      Citations: 30     Fields:    Translation:AnimalsCells
    150. Poo WJ, Hartshorne DJ. Actin crosslinked with glutaraldehyde: evidence to suggest an active role for actin in the regulatory mechanism. Biochem Biophys Res Commun. 1976 May 17; 70(2):406-12. PMID: 132931.
      Citations: 1     Fields:    Translation:Cells
    151. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology. 44:158-176.
    152. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. European Journal of Cancer. 51:2689-2697.
    153. Treatment of BRAF-mutated advanced cutaneous melanoma. Chinese Clinical Oncology. 3.
    154. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. Journal of Clinical Oncology. 34:4102-4109.
    155. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. Ophthalmic Plastic and Reconstructive Surgery.
    156. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma. Investigational New Drugs.
    157. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. Journal of Clinical Oncology. 34:1510-1517.
    158. Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma. Oncology Reviews. 2:183-193.
    159. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Research.
    160. Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma. Cancer immunology research. 3:1201-1206.
    161. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.
    162. Metastases to abdominal-pelvic organs. 563-575.
    163. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Research.
    164. The Rajkumar article reviewed. Oncology. 15:879.
    165. Melanoma. 633-652.
    166. Combining targeted therapy with immunotherapy (interferon-α) rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies. OncoImmunology. 1:773-776.
    167. Temozolomide plus pegylated interferon-α-2b in patients with metastatic melanoma. American Journal of Oncology Review. 5:680-683.
    HWU's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (472)
    Explore
    _
    Co-Authors (89)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _